GW Phar­ma's cannabis-de­rived epilep­sy med­i­cine makes the cut in the Eu­ro­pean Union

GW Phar­ma’s cannabis-de­rived med­i­cine for epilep­sy has won Eu­ro­pean en­dorse­ment, more than a year af­ter the British drug­mak­er se­cured its land­mark US ap­proval.

The med­i­cine, chris­tened Epidy­olex in the EU, is a plant-de­rived for­mu­la­tion of cannabid­i­ol (CBD). It was ap­proved in June by the US au­thor­i­ties and launched in the re­gion in No­vem­ber. The Lon­don-based com­pa­ny gen­er­at­ed near­ly $102 mil­lion sell­ing the drug in the first half of this year — and has treat­ed over 12,000 pa­tients in the Unit­ed States.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER